Challenging the status quo to improve the translational potential of preclinical oncology studies

Kate Connor; Anna Golebiewska; Annette T. Byrne

doi:10.1038/s41568-024-00756-w

Challenging the status quo to improve the translational potential of preclinical oncology studies

Kate Connor, Anna Golebiewska, Annette T. Byrne^*

^*Corresponding author for this work

NORLUX Neuro-Oncology Laboratory

Research output: Contribution to journal › Comment/debate

Abstract

The precision medicine era has precipitated inherent new challenges to the preclinical tumour biology field. Overall, continued poor clinical translatability of preclinical studies highlights the need to disrupt the status quo. Well-characterized models, ideally established in the orthotopic setting and, where feasible, treated with classical standard-of-care regimens, are mandated.

Original language	English
Article number	9204
Pages (from-to)	3-4
Number of pages	2
Journal	Nature Reviews Cancer
Volume	25
Issue number	1
Early online date	7 Oct 2024
DOIs	https://doi.org/10.1038/s41568-024-00756-w
Publication status	Published - Jan 2025

Access to Document

10.1038/s41568-024-00756-w

Cite this

@article{b4265e45332a43fba44f96c25f65d0a7,

title = "Challenging the status quo to improve the translational potential of preclinical oncology studies",

abstract = "The precision medicine era has precipitated inherent new challenges to the preclinical tumour biology field. Overall, continued poor clinical translatability of preclinical studies highlights the need to disrupt the status quo. Well-characterized models, ideally established in the orthotopic setting and, where feasible, treated with classical standard-of-care regimens, are mandated.",

author = "Kate Connor and Anna Golebiewska and Byrne, {Annette T.}",

note = "Acknowledgements The authors acknowledge funding from the European Union Horizon 2020 research and innovation program {\textquoteleft}GLIORESOLVE{\textquoteright} (grant agreement no. 101073386). Funding is further acknowledged from Science Foundation Ireland (grants 18/RI/5759, 20/FFP-P/8884 and 20/FFP-P/8613), the Irish Health Research Board (grants ILP-POR-2019-066 and ILP-POR-2022-007), the Irish Higher Education Authority North South Research Program {\textquoteleft}RADCOL{\textquoteright} and the Luxembourg National Research Fund (C20/BM/14646004/GLASSLUX). Additional financial support is acknowledged from the Beaumont Hospital, Dublin Foundation, Brain Tumour Ireland and a private research funding donation (to A.T.B.). Publisher Copyright: {\textcopyright} Springer Nature Limited 2024.",

year = "2025",

month = jan,

doi = "10.1038/s41568-024-00756-w",

language = "English",

volume = "25",

pages = "3--4",

journal = "Nature Reviews Cancer",

issn = "1474-175X",

publisher = "Nature Publishing Group",

number = "1",

}

TY - JOUR

T1 - Challenging the status quo to improve the translational potential of preclinical oncology studies

AU - Connor, Kate

AU - Golebiewska, Anna

AU - Byrne, Annette T.

N1 - Acknowledgements The authors acknowledge funding from the European Union Horizon 2020 research and innovation program ‘GLIORESOLVE’ (grant agreement no. 101073386). Funding is further acknowledged from Science Foundation Ireland (grants 18/RI/5759, 20/FFP-P/8884 and 20/FFP-P/8613), the Irish Health Research Board (grants ILP-POR-2019-066 and ILP-POR-2022-007), the Irish Higher Education Authority North South Research Program ‘RADCOL’ and the Luxembourg National Research Fund (C20/BM/14646004/GLASSLUX). Additional financial support is acknowledged from the Beaumont Hospital, Dublin Foundation, Brain Tumour Ireland and a private research funding donation (to A.T.B.). Publisher Copyright: © Springer Nature Limited 2024.

PY - 2025/1

Y1 - 2025/1

N2 - The precision medicine era has precipitated inherent new challenges to the preclinical tumour biology field. Overall, continued poor clinical translatability of preclinical studies highlights the need to disrupt the status quo. Well-characterized models, ideally established in the orthotopic setting and, where feasible, treated with classical standard-of-care regimens, are mandated.

AB - The precision medicine era has precipitated inherent new challenges to the preclinical tumour biology field. Overall, continued poor clinical translatability of preclinical studies highlights the need to disrupt the status quo. Well-characterized models, ideally established in the orthotopic setting and, where feasible, treated with classical standard-of-care regimens, are mandated.

UR - http://www.scopus.com/inward/record.url?scp=85205800969&partnerID=8YFLogxK

UR - https://pubmed.ncbi.nlm.nih.gov/39375534/

U2 - 10.1038/s41568-024-00756-w

DO - 10.1038/s41568-024-00756-w

M3 - Comment/debate

C2 - 39375534

AN - SCOPUS:85205800969

SN - 1474-175X

VL - 25

SP - 3

EP - 4

JO - Nature Reviews Cancer

JF - Nature Reviews Cancer

IS - 1

M1 - 9204

ER -

Challenging the status quo to improve the translational potential of preclinical oncology studies

Abstract

Access to Document

Other files and links

Fingerprint

Cite this